Zafgen says another patient dies in obesity drug trial; Negative news about statins affects their use, study finds;

> Zafgen ($ZFGN), the drugmaker that suspended an obesity drug trial in October after a patient died, said another trial participant has perished, this time from a blocked artery in the lung. Report

> Negative news about the risks or side effects of statin drugs prompts people to ratchet back their use of the drug, increasing risks of heart attacks and strokes, a new study found. Report

> BioMarin Pharmaceutical ($BMRN) is still optimistic about approval prospects for its Duchenne muscular dystrophy drug, which came in for intense criticism at an FDA advisory panel meeting last week. Report

> Horizon Pharma ($HZNP) nabbed European approval for Ravicti, its new add-on drug for urea cycle disorders. Report

And Finally... Forget Adderall for a workplace boost; some Silicon Valley workers reportedly are taking small doses of the psychedelic drug LSD to make themselves more productive. Report

Suggested Articles

Moving into the Final Four of the #FierceMadness drug name tournament, contenders from both Big Pharma and smaller companies remain evenly in play.

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.